Ugurlucan M, Yerebakan C, Furlani D, Ma N, Steinhoff G
Department of Cardiac Surgery, Rostock University Medical Faculty, Rostock, Germany.
Thorac Cardiovasc Surg. 2009 Mar;57(2):63-73. doi: 10.1055/s-2008-1039235. Epub 2009 Feb 24.
The heart has long been regarded as a post-mitotic organ. Since many years, physicians have focused on developing strategies to restore the myocardium after ischemic damage followed by ventricular dysfunction. Restoration is generally achieved through the redirection of blood flow or by supporting contractile performance. The discovery of stem cells capable of generating angiogenic or contractile cells and structures offers new horizons to patients suffering from myocardial disease. Experimental studies indicate that the delivery or mobilization of stem and progenitor cells may improve tissue perfusion and the contractile performance of the damaged heart. Another aspect of restoration is based on cardiovascular tissue engineering and the creation of three-dimensional biological conformations to replace the artificial materials frequently used during operations, i.e., valves and grafts, or even a portion of the nonfunctional myocardial tissue. At present, the underlying intra- and intercellular molecular mechanisms controlling myocardiogenesis and cardiomyocyte replacement during regenerative processes are not very well understood. In this brief review we try to give the answers to questions on certain aspects of myocardial tissue regeneration and engineering procedures.
长期以来，心脏一直被视为一个有丝分裂后器官。多年来，医生们一直致力于制定策略，以在缺血性损伤后恢复心肌，继而改善心室功能。恢复通常通过重新引导血流或支持收缩功能来实现。能够生成血管生成细胞或收缩性细胞及结构的干细胞的发现，为患有心肌疾病的患者带来了新的希望。实验研究表明，干细胞和祖细胞的递送或动员可能改善受损心脏的组织灌注和收缩功能。恢复的另一个方面基于心血管组织工程以及创建三维生物结构，以替代手术中经常使用的人工材料，即瓣膜和移植物，甚至是部分无功能的心肌组织。目前，对于再生过程中控制心肌发生和心肌细胞替代的细胞内和细胞间分子机制，人们了解得还不是很透彻。在这篇简短的综述中，我们试图回答有关心肌组织再生和工程程序某些方面的问题。
